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Cognitive disorders of later life are potentially devastating. To estimate the relationship between satu-
rated and trans fat intake and risk of cognitive disorders. PubMed, EMBASE, and the Cochrane Central
Register of Controlled Trials were searched for studies reporting saturated or trans fat intake and incident
dementia, Alzheimer’s disease (AD), or mild cognitive impairment (MCI) or cognitive decline. Only
observational studies met the inclusion criteria: 4 for AD or other dementias, 4 for MCI, and 4 for
cognitive decline. Saturated fat intake was positively associated with AD risk in 3 of 4 studies, whereas
the fourth suggested an inverse relationship. Saturated fat intake was also positively associated with total
dementia in 1 of 2 studies, with MCI in 1 of 4 studies, and with cognitive decline in 2 of 4 studies.
Relationships between trans fat intake and dementia were examined in 3 reports with mixed results.
Several, although not all, prospective studies indicate relationships between saturated and trans fat
intake and risk of cognitive disorders.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Dementia is a devastating condition, and means of prevention
are urgently needed. Its most common form, Alzheimer’s disease
(AD), affected an estimated 4.7million Americans aged 65 years and
older in 2010, a ﬁgure expected to reach 13.8 million by 2050
(Hebert et al., 2013).
Several studies have identiﬁed an association between saturated
or trans fat intake and risk of dementia, including AD (Laitinen et al.,
2006; Luchsinger et al., 2002; Morris et al., 2003). The Chicago
Health and Aging Project, which studied a group of 815 individuals
aged 65 years and older at baseline, identiﬁed positive associations
between saturated and trans fat intake and risk of developing AD
(Morris et al., 2003). Studies in New York and Finland also showed
increased dementia risk with increased saturated fat intake
(Laitinen et al., 2006; Luchsinger et al., 2002). However, a report
from the Rotterdam Study showing increased dementia risk with
increasing saturated fat intake after 2.1 years of follow-up (Kalmijn
et al., 1997) was contradicted by a report from the same cohort after
6 years of follow-up (Engelhart et al., 2002a).BY-NC-ND license (http://
r Responsible Medicine, 5100
USA. Tel.: þ1 202 527 7303;
).
Published by Elsevier Inc. All righStudies have also investigated dietary factors related to risk of
mild cognitive impairment (MCI), a condition that has been codiﬁed
relatively recently (Petersen, 2011; Petersen et al., 1999) and which,
for some people, may be preliminary to AD. In a Finnish study,
saturated fat intake was associated with increased risk (Eskelinen
et al., 2008), whereas studies in Italy (Solfrizzi et al., 2006a),
Australia (Cherbuin and Anstey, 2012), and the United States (US)
(Roberts et al., 2012) showed no such association.
We therefore undertook a systematic review to identify the
strength of associations between saturated or trans fat intake and
the risk of AD and other forms of dementia, MCI, and cognitive
decline. We hypothesized that evidence from prospective studies
would indicate that higher intake of saturated or trans fat is asso-
ciated with increased risk of dementia, AD, and MCI, and with a
greater degree of cognitive decline in later life. This review was
registered on PROSPERO (registration number CRD42012003270)
on November 12, 2012.2. Methods
We searched the published scientiﬁc literature for prospective
cohort studies and randomized controlled trials of adult human
subjects reporting saturated fat or trans fat intake and the end-
points of incident dementia, AD, or mild cognitive impairment; or
decline in cognitive function in later life, using disease incidence
or cognitive change in reference populations differing in intake of
these fats as the primary comparator.ts reserved.
Fig. 1. Study-ﬂow diagram showing the number of studies assessed for eligibility and included in the review.
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Articles were identiﬁed by searches of PubMed (1946 through
July 16, 2012), EMBASE (1947 through July 17, 2012), and the
Cochrane Central Register of Controlled Trials (1966 through July
19, 2012). For inclusion in the systematic review, articles had to
meet the following criteria: exposure to saturated or trans fats was
quantiﬁed (at any adult age); endpoints included incident demen-
tia, AD, or MCI; or cognitive decline; the outcome was identiﬁed in
older age (as opposed to early dementia occurring in cases of Down
syndrome, e.g.,); in prospective studies, an interval of at least 1 year
occurred between dietary assessment and determination of
cognitive outcome (dementia, AD, MCI) or in studies assessing
cognitive decline, between 2 or more assessments of cognitive
status. There were no restrictions regarding the gender, race, or
ethnicity of participants or on language, sample size, publication
status, or publication date. Case reports, case series, case-control
studies, and studies limited to individuals with medicalconditions (e.g., dyslipidemia, cardiovascular disease) likely to in-
ﬂuence cognitive status and intervention trials including non-
dietary methods (e.g., exercise) were excluded because of the
potential for bias or confounding in their study designs.
The following syntax was used for the PubMed search: (“fatty
acids”[MeSH Term] OR fatty acids[Text Word] OR fat[Text Word]
OR saturated fat[Text Word] OR partially hydrogenated[Text
Word] OR “trans fatty acids”[MeSH Term] OR trans fat[Text
Word]) AND (“alzheimer disease”[MeSH Term] OR Alzheimer’s
disease[Text Word] OR dementia[MeSH Term] OR dementia[Text
Word] OR cognitive decline[Text Word] OR cognitive change[Text
Word] OR cognitive function[Text Word] OR cognitive impair-
ment[Text Word]) AND (“humans”[MeSH Term]). Analogous
search terms were used to search EMBASE and the Cochrane
Central Register of Controlled Trials.
Two researchers (Neal D. Barnard and Anne E. Bunner) inde-
pendently reviewed the titles and abstracts of the citations pro-
duced by the search. For citations appearing to meet the inclusion
Table 1
Summary of prospective studies on saturated and trans fat intake and incident Alzheimer’s disease and other forms of dementia
Study, N Baseline age, gender,
race, APOE status
Duration,
mean (y)
Saturated fat and trans fat intake Dementia
cases
Results and conclusions
Rotterdam study, the
Netherlands (Engelhart
et al. 2002a), N ¼ 5395
Mean 67.7 y, 59% women,
race not reported,
APOE not reported.
Primary education 35%
6 Mean, 34.4 g/d (SD, 7.2)
Mean trans fat: 2.7 g/d (SD, 1.0)
Total: 197
AD: 146
Vascular: 29
Others: 22
Rate ratios per SD increase
in intake (95% CI)
For total dementia:
SFA: 0.91 (0.79e1.05)
Trans fat: 0.90 (0.77e1.06)
For Alzheimer’s disease:
SFA: 0.83 (0.70e0.98)
Trans fat: 0.80 (0.65e0.97)
For vascular dementia:
SFA: 1.03 (0.73e1.46)
Trans fat: 1.01 (0.71e1.44)
Washington HeightseInwood
Columbia Aging Project
New York, USA (WHICAP)
(Luchsinger et al., 2002)
N ¼ 980
Mean 75.3 y, 67% women,
25% nonHispanic white,
32% nonHispanic black,
43% Hispanic, 28% APOE ε4.
Mean of education 9 y
4 SFA quartiles not reported.
Mean total fat intake 38 g/d
AD: 242 HR for AD for SFA quartile 1
versus 4: 1.3 (95% CI, 0.9e1.9);
p ¼ 0.08 for trend.
Association between total fat
and AD risk was signiﬁcant only
in those with APOE ε4. This
relationship was not
reported for SFA.
Chicago Health and Aging
Project (CHAP) Chicago,
USA (Morris et al., 2003)
N ¼ 815
Mean 73.1 y, 61% women,
52% black, 35% APOE ε4.
Mean of education 12.6 y
3.9 SFA quintiles, median:
Q1: 13 g/d
Q5: 26 g/d
Trans fat quintiles, median:
Q1: 1.8 g/d
Q5: 4.8 g/d
AD: 131 Relative risk of AD for Q1
versus Q5 (95% CI in
parenthesis):
SFA: 2.2 (1.1e4.7)a; p ¼ 0.09
for trend.
Trans fat: 2.5 (1.0e6.2)a;
p ¼ 0.21 for trend.
APOE status did not
inﬂuence results.
Cardiovascular risk factors,
Aging and Dementia
(CAIDE) study, Finland
(Laitinen et al., 2006)
N ¼ 1449
Mean 50.4 y, 62% women,
race not reported, 35% APOE ε4.
Mean education 8.6 y
21 Quartiles of SFA from spreads:
Q1: 4.1 g/d
Q4: >15.8 g/d
Spreads and milk products contributed
approximately half the fat in the diet.
Total: 117
AD: 76
For dementia:
OR for SFA Q1 versus Q4:
2.74 (0.65e11.56).
For AD:
OR for SFA Q1 versus Q4:
2.34 (0.51e10.74).
SFA intake was associated
with increased dementia
risk mainly in APOE ε4 carriers.
For studies with comparisons at multiple levels of statistical control, ﬁgures listed are for models with the highest levels of control.
Key: AD, Alzheimer’s disease; CI, conﬁdence interval; HR, hazard ratio; OR, odds ratio; Q1, lowest intake quartile or quintile; Q4, highest intake quartile; Q5, highest intake
quintile; SD, standard deviation; SFA, saturated fat.
a Data from Model 2, multivariable analysis.
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articles to identify eligible studies. Disagreements were resolved
by consensus. From the reference lists of reviewed articles and
through contacts with research experts, additional articles were
identiﬁed and reviewed for eligibility, and, when possible, authors
of the identiﬁed articles were contacted for additional information.
2.2. Data extraction
Two investigators (Neal D. Barnard and Anne E. Bunner) inde-
pendently extracted data from the selected studies, using a data-
extraction table, which was piloted using 10 references and
revised accordingly. The extracted data included study location,
participant numbers, demographics, APOE status, study dates and
duration, diet assessment method, baseline diet characteristics,
cognitive outcomes and assessment methods, and relative risk of
cognitive outcomes or degree of cognitive change related to dietary
exposure. Differences were settled by consensus.
2.3. Outcome measures
The principal outcomes of interest were incident dementia, AD,
or MCI or cognitive decline, using comparison population groups
that differed in intake of saturated or trans fats or, for controlled
trials, untreated control groups, if available.2.4. Quality measures
Study reports were examined for means of dietary assessment,
diagnosis and cognitive assessment, sample size, baseline dietary
variability, attrition, and statistical measures.3. Results of search
The PubMed search yielded 1772 citations, the EMBASE search
yielded 3794 citations, and the Cochrane Central Register of
Controlled Trials search yielded 47 citations. After removal of du-
plicates, 4639 citations remained. An additional 13 articles were
identiﬁed from reference lists and research experts. The disposition
of these articles is described in Fig. 1.
The articles meeting the inclusion criteria represented the
following: AD and other forms of dementia were the subjects of 4
prospective studies, which took place in Finland, the Netherlands,
and the US, of which one produced reports at 2 time points
(Engelhart et al., 2002a; Kalmijn et al., 1997; Laitinen et al., 2006;
Luchsinger et al., 2002; Morris et al., 2003). MCI was the subject
of 4 prospective studies taking place in Australia, Finland, Italy,
and the US (Cherbuin and Anstey, 2012; Eskelinen et al., 2008;
Roberts et al., 2012; Solfrizzi et al., 2006a). Cognitive decline
was the subject of 4 prospective studies, which took place in Italy
and the US (Morris et al., 2004; Naqvi et al., 2011; Okereke et al.,
Fig. 2. Baseline age of participants and duration of prospective studies of diet and incident Alzheimer’s disease.
N.D. Barnard et al. / Neurobiology of Aging 35 (2014) S65eS73S682012; Solfrizzi et al., 2006b). These studies are described in the
following and in Tables 1e3. We identiﬁed no clinical trials that
met the inclusion criteria.3.1. AD and other forms of dementia
The Rotterdam Study included 5395 residents of the
Netherlands aged 55 years (mean baseline age 67.7 years). Prev-
alence of the APOE ε4 allele was not reported. In an initial report
after a 2.1-year follow-up period, 58 cases of dementia were iden-
tiﬁed, including 37 cases of AD with no vascular component, 12
cases of vascular dementia, and 9 cases of dementia of other types
(Kalmijn et al., 1997). Total dementia, vascular dementia, and AD
were each positively related to saturated fat intake, but the trend
reached statistical signiﬁcance only for vascular dementia. A second
Rotterdam Study report after 6 years of observation identiﬁed 197
cases of dementia, including 146 with AD, 29 with vascular de-
mentia, and 22 with other types (Engelhart et al., 2002a). In
contrast to the earlier report, total dementia risk and vascular de-
mentia risk were not related to saturated or trans fat intake,
although AD risk was negatively associated with saturated and
trans fat intake (Table 1, Fig. 2).
The Washington HeightseInwood Columbia Aging Project
(WHICAP) included 980 New Yorkers aged65 years, of whom 28%
carried the APOE ε4 allele (Luchsinger et al., 2002). After 4 years of
follow-up, 242 cases of AD were identiﬁed. Alzheimer’s risk was
positively, but nonsigniﬁcantly, associatedwith saturated fat intake.
A subanalysis based on genetic type showed the relationships be-
tween energy intake or total fat intake and Alzheimer’s risk were
primarily found in those with the APOE ε4 allele. This subanalysis
was not done for saturated fat intake.
The Chicago Health and Aging Project (CHAP) reported on a
stratiﬁed sample of 815 individuals in Chicago, IL, aged
65e94 years (mean 73.1 years), of whom 35% carried the APOE ε4
allele (Morris et al., 2003). After 3.9 years of observation, 131
Alzheimer’s cases were identiﬁed. Intake levels of both saturated
and trans fat were positively and signiﬁcantly associated with
Alzheimer’s risk.
The Cardiovascular risk factors, Aging and Dementia (CAIDE)
study included 1449 individuals in Finland with a mean baseline
age of 50.4 years, of whom 35% carried the APOE ε4 allele
(Laitinen et al., 2006). After a follow-up of 21 years, 117 cases of
dementia were identiﬁed, including 76 with AD. Moderate satu-
rated fat intake was positively and signiﬁcantly associated with
both total dementia and AD, but the association did not reach
statistical signiﬁcance for the highest saturated fat intake group.
In a subanalysis based on APOE status, elevated risk of AD or
dementia related to saturated fat intake appears to have beenmainly evident in APOE ε4 carriers; among carriers with moder-
ate (second quartile) saturated fat intake, the odds ratio for
incident dementia was 3.16 (95% conﬁdence interval [CI],
1.12e8.91).
3.2. Mild cognitive impairment
The CAIDE study, in its 2008 report, reported ﬁndings from 1341
participants with a mean baseline age of 50.2 years (standard de-
viation, 6.0) (Eskelinen et al., 2008). After a mean follow-up of
21 years, 82 cases of MCI, deﬁned by the Mayo Clinic Alzheimer’s
Disease Research Center criteria (Smith et al., 1996), were identiﬁed.
Saturated fat intake was positively and signiﬁcantly associated with
MCI risk, particularly amongwomen. A subanalysis showed that the
association between saturated fat intake and MCI was limited to
participants with the APOE ε4 allele (odds ratio ¼ 5.06, 95% CI,
1.35e18.94).
The Italian Longitudinal Study on Aging (ILSA) included 278
participants with a mean baseline age of 73 years (Solfrizzi et al.,
2006a). After a mean follow-up of 2.6 years, and using an MCI
deﬁnition slightly modiﬁed from Petersen et al. (1999) in which
subjective memory impairment was not required and noncognitive
disabilities and comorbid illnesses were allowed, 18 cases of MCI
were identiﬁed. Saturated fat intake was not associated with MCI
risk and APOE status was not reported.
The Personality and Total Health (PATH) Through Life Study
included 1528 residents of Australia with a mean baseline age of
62.5 years (Cherbuin and Anstey, 2012). After a 4-year follow-up, 10
cases of MCI, diagnosed using the criteria of Jack et al. (1999) were
identiﬁed. Saturated fat intake was not associated with MCI risk.
APOE ε4 status was controlled for in analyses, but data for APOE ε4
carriers were not reported separately.
The Rochester Epidemiology Project included 937 Minnesota
residents with a median baseline age of 79.5 years (Roberts et al.,
2012). After a median follow-up of 3.7 years, 200 cases of inci-
dent MCI based on criteria from Petersen (2004) or dementia
(192 MCI, 8 dementia) were identiﬁed. Higher saturated fat
intake was associated with reduced risk of MCI, which was no
longer signiﬁcant after further adjustment for potential con-
founders, including APOE status (Table 2). Higher trans fat intake
was associated with nonsigniﬁcantly reduced MCI risk.3.3. Cognitive decline
The CHAP study, in its 2004 report, included ﬁndings from 2560
individuals with a mean baseline age of 74 years (Morris et al.,
2004). Cognitive function was described with a composite of 4
cognitive tests. Over a 6-year period, a high saturated fat intake
Table 2
Summary of prospective studies on saturated and trans fat intake and incident mild cognitive impairment
Study, N Baseline age, gender, race, APOE
status
Duration (y) Saturated fat intake MCI cases Results and conclusions
Cardiovascular risk factors,
Aging and Dementia (CAIDE)
study, Finland (Eskelinen
et al., 2008) N ¼ 1341
Mean 50.2 y, 62% women, race
not reported, APOE not
reported.
Mean education of 8.7 y
Mean, 21 SFA from milk products and
spreads.
Low: 21.6 g/d
High: >21.6 g/d
82 OR for MCI (95% CI)
All participants
High SFA: 2.36 (1.17e4.74)
Among women
High SFA: 3.20 (1.13e9.06)
Among people with APOE ε4
allele.
High SFA: 5.06 (1.35e18.94)
Italian Longitudinal Study on
Aging Italy (Solfrizzi et al.,
2006a), N ¼ 278
Mean 73.0 y, 45% women, race
not reported, APOE not
reported.
Mean education 4 y
Median, 2.6 Median SFA:
19.24 g/d
SFA quartiles:
Q1: 15.5 g/d
Q4: 24.3 g/d
18 HR (95% CI) for MCI for Q1
versus Q4: 0.86 (0.21e3.49);
p ¼ 0.85 for trend.
PATH Through Life Study,
Australia
(Cherbuin and Anstey, 2012),
N ¼ 1528
Mean 62.5 y, 51% women, 97.5%
white, race not reported, APOE
not reported.
Mean education of 14.1 y
4 Baseline dietary intake not
speciﬁed.
10 OR (95% CI) for MCI per SD of
SFA intake:
1.15 (0.45e2.94); p ¼ 0.772.
APOE status was controlled for
in analyses.
Rochester Epidemiology
Project, Minnesota, USA
(Roberts et al., 2012), N ¼
937
Median 79.5 y, 49% women,
race not reported, 21.5% APOE
ε4.
Mean education of 14.1 y
Median, 3.7 Mean SFA, 10.5 en%
SFA quartiles:
Q1: <8.4 g/d
Q4: >12 g/d
Trans fat quartiles:
Q1: <0.23 g/d
Q4: >0.57 g/d
192a HR (95% CI) for MCI for SFA Q1
versus Q4: 0.64 (0.39e1.05);
p ¼ 0.25 for trend.
HR (95% CI) for MCI, for trans fat
Q1 versus Q4: 0.82 (0.52e1.30);
p ¼ 0.84 for trend.
Adjusted for APOE in statistical
models.
For studies with comparisons at multiple levels of statistical control, ﬁgures listed are for models with the highest levels of control.
Key: 95% CI, 95% conﬁdence interval; en%, percent of total energy intake; HR, hazard ratio; MCI, mild cognitive impairment; OR, odds ratio; Q1, lowest intake quartile; Q4,
highest intake quartile; SFA, saturated fat.
a In addition to 192 incident MCI cases, dementia was identiﬁed in 8 participants; these participants were included in the remaining analyses.
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tion in cognitive function. APOE status was not measured and thus
not available for analyses (Table 3).
The Cognitive Change in Women study included 482 partici-
pants with a mean baseline age of 71 years who were tested for
memory, vision, executive function, language, and attention (Naqvi
et al., 2011). Over a 3-year interval, saturated fat intake and trans fat
intake were not associated with cognitive decline. APOE status was
included in the statistical analysis, but did not show an effect on the
relationship between saturated fat intake and cognitive change.
The Italian Longitudinal Study on Aging (ILSA study), in its 2006
report on diet and cognitive decline included 278 individuals with a
mean baseline age of 73 years (Solfrizzi et al., 2006b). Cognitive
function was evaluated using the Mini-Mental Status Examination.
After an interval of 8.5 years, saturated fat intakewas not associated
with cognitive change and APOE status was not reported.
The Women’s Health Study included 6183 participants with an
average baseline age of 72 years (Okereke et al., 2012). Cognitive
function was assessed in telephone interviews testing general
cognition, verbal memory, and semantic ﬂuency. Over a 4-year
period, higher saturated fat intake was associated with worse tra-
jectory in global cognitive function and verbal memory. However,
APOE status was not reported.
In summary, saturated fat intake was positively associated with
AD risk in 3 of 4 cohort studies (Laitinen et al., 2006; Luchsinger et al.,
2002; Morris et al., 2003), whereas the fourth suggested an inverse
relationship (Engelhart et al., 2002a). Saturated fat intake was also
positively associatedwith total dementia in 1 (Laitinen et al., 2006) of
2 studies, withMCI in 1 (Eskelinen et al., 2008) of 4 studies, and with
cognitive decline in 2 (Morris et al., 2004; Okereke et al., 2012) of 4
studies. Relationships between trans fat intake and AD were exam-
ined in only 2 reports with mixed results (Engelhart et al., 2002a;
Morris et al., 2003), and the relationship between trans fat intake
and total dementia was described in only one study with a nonsig-
niﬁcantly negative ﬁnding (Engelhart et al., 2002a).3.4. Study quality
Studies of AD and other dementia types varied in size and
duration of follow-up. Cohort sizes ranged from 815 to 5395, and
follow-up periods varied from 2.1 to 21 years. All studies
assessed dietary intake by food frequency questionnaires, except
for the CAIDE study, which used a 20-item dietary questionnaire
limited to questions about dairy products and spreads (Laitinen
et al., 2006). Diagnosis of dementia was made based on indi-
vidual examinations; the Rotterdam study also used medical
records when participants were unavailable or deceased. For
diagnosis of AD, all studies used the same established criteria
(McKhann et al., 1984).
In studies of MCI, cohort sizes ranged in size from 278 to 1528.
All studies assessed dietary intake using food frequency question-
naires, except for the CAIDE study, which as noted previously, used
a 20-item dietary questionnaire limited to questions about dairy
products and spreads (Laitinen et al., 2006). In all studies, MCI
diagnosis was done by clinical examination, using criteria devel-
oped by Petersen (2004) or modiﬁcations of them (Smith et al.,
1996).
Studies of cognitive decline were less uniform. Study sizes
ranged from 278 to 6183, with observation periods ranging from 3
to 8.5 years. Methods for assessing of cognition varied from study to
study.
Because the means for reporting the relationships between di-
etary intake and cognitive endpoints varied substantially between
studies, a meta-analysis was not possible.
4. Discussion
Several studies report relationships between saturated and trans
fat intake and cognitive disorders. However, the divergence in
ﬁndings between the various studies merits examination. All 4
cohort studies investigating relationships between diet and
Table 3
Summary of prospective studies on saturated and trans fat intake and cognitive decline
Study, N Baseline age, gender, race, APOE status Duration (y) Saturated fat
and trans fat intake
Cognitive tests Results
Chicago Health and Aging
Project (CHAP), USA
(Morris et al., 2004),
N ¼ 2560
Mean 74.0 y, 63.9% women,
58% black, APOE status was
not included in this report.
Mean education of 12.4 y
Median, 5.6 Mean SFA: 18.1 g/d
SFA quintiles:
Q1: <12.2 g/d
Q5: >24.3 g/d
Trans fat quintiles:
Q1: <2.1 g/d
Q5: >4.9 g/d
Composite of 4 tests:
East Boston Tests of Immediate
and Delayed Recall
MMSE
Symbol Digit Modalities Test
SFA:
SFA Q1 versus Q5 associated with a
difference
in rate of cognitive change of 0.023
SU/y; p ¼ 0.06 for difference; p ¼ 0.04
for trend.
Trans fats:
Q1 versus Q5: 0.020; p ¼ 0.07 for
difference; p ¼ 0.07 for trend.
Cognitive Change in Women,
USA Naqvi et al. (2011) N ¼ 482
Mean 70.9 y, 100% women,
87% white, APOE details
not reported.
Education (%):
Less than or equal to
high school, 20%
Some college, 24%
Greater than or equal to
college degree, 56%
Mean, 2.9 SFA median, 11.1 en%
SFA quartiles:
Q1: 9.12 g/d
Q4: 13.01 g/d
Trans fat quartiles:
Q1: 1.45 g/d
Q4: 2.65 g/d
Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD)
word list learning, constructions,
and word ﬂuency tests; Wechsler
Memory Scale-Revised Logical Memory,
Visual Reproduction, and Digit Span
tests;
Boston Naming Test; F-A-S Word
Fluency
and Judgment of Line Orientation tests;
Visual Target Cancellation Test;
Trail Making Test Part A and B;
Visual-Verbal test
Baseline scores were standardized
to zero mean and unit SD (Z-scores).
Change in cognitive function score by
intake quartiles.
SFA:
Q1: 0.20 (SE, 0.05)
Q4: 0.13 (SE, 0.04)
p ¼ 0.69
Trans fats:
Q1: 0.17 (SE, 0.04)
Q4: 0.17 (SE, 0.04)
p ¼ 0.54
APOE status did not inﬂuence the
relationship between saturated fat
intake and cognitive change.
Italian Longitudinal Study
on Aging, Italy (Solfrizzi et al.,
2006b), N ¼ 278
Mean 73.0 y, 45% women, race
not reported, APOE not reported.
Mean education of 4 y
Median, 8.5 Mean, 20.8 g/d (SD, 7.8) Mini-Mental Status Examination Estimated change in cognitive function
(b and 95% CI) per SD intake per 4 y
increment:
0.001 (0.003 to 0.001) (lower scores
indicate better function)
Women’s Health Study,
USA Okereke et al. (2012),
N ¼ 6183
Mean of 71.9 y, 100% women,
94%e97% white, APOE not reported.
Education: 34% college degree
4 SFA: median, 9.8 en%
SFA quintiles:
Q1: median, 7.0 en%
Q5: median, 13.1 en%
Trans fat: median, 1.04 en%
Trans fat quintiles:
Q1: median, 0.55 en%
Q5: median, 1.84 en%
(1) Telephone Interview for
Cognitive Status (TICS); (2)
immediate trials of the East
Boston Memory Test (EBMT);
(3) delayed recall trials of the
EBMT; (4) delayed recall trial
of the TICS 10-word list; and
(5) category ﬂuency
Testing done by telephone.
SFA Q5 versus Q1 had a mean 4 y
difference in global cognitive change of
0.12 (0.20 to 0.03) and in verbal
memory of 0.13 (0.23 to 0.03).
OR (95%CI) of worst (lowest 10%)
cognitive change over 4 y.
SFA Q5 versus Q1:
Global: 1.64 (1.04e2.58); p ¼ 0.02 for
trend.
Verbal: 1.65 (1.04e2.61); p ¼ 0.02 for
trend.
Trans fat Q5 versus Q1 had a mean 4 y
difference in global cognitive change of
0.02 (0.05 to 0.09) and in verbal
memory of 0.04 (0.05 to 0.12).
OR (95%CI) of worst (lowest 10%)
cognitive change over 4 y.
Trans fat Q5 versus Q1:
Global: 0.76 (0.52e1.11); p ¼ 0.49 for
trend
Verbal: 0.72 (0.49e1.06); p ¼ 0.32 for
trend
For studies with comparisons at multiple levels of statistical control, ﬁgures listed are for models with the highest levels of control.
Key: 95% CI, 95% conﬁdence interval; en%, percent of total energy intake; OR, odds ratio; Q1, lowest intake quartile or quintile; Q4, highest intake quartile; Q5, highest intake quintile; SD, standard deviation; SE, standard error;
SFA, saturated fat; SU, standard unit.
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criteria. The following factors may have been contributors to the
observed heterogeneity.
Age and duration of observation: at the end of the observation
period, the Rotterdam Study participants were younger (mean age
73.7 years) comparedwith 79.3 years forWHICAP and 77.0 years for
CHAP. CAIDE participants were also relatively young (71.3 years).
However, the CAIDE study included a long (21 years) observation
period, which would have been expected to capture a larger
number of cases.
Race: the racial composition of the cohorts varied; 32% of
WHICAP participants and 52% of CHAP participants were black.
Race was not described in either the Rotterdam Study or CAIDE, but
presumably these northern European cohorts were largely white. In
CHAP, the association between saturated fat intake and AD risk was
found primarily in black participants (Morris et al., 2003). If the
association between saturated fat intake and AD risk is less robust
inwhite participants, this could help explain the lower case-ﬁnding
in the Rotterdam Study and CAIDE.
APOE status: in the WHICAP and CAIDE studies, the Alzheimer’s
risk related to saturated fat intake was largely conﬁned to in-
dividuals with the APOE ε4 allele (Laitinen et al., 2006; Luchsinger
et al., 2002). In CHAP, APOE ε4 status had no signiﬁcant effect on
this relationship (Morris et al., 2003). APOE status was not reported
in the Rotterdam Study. If the relationship between saturated fat
intake and AD risk is inﬂuenced by APOE status, it might be
obscured in studies that do not account for genetic variability.
Diet: baseline saturated fat intake appears to have been higher
in the Rotterdam Study than in CHAP or CAIDE. Reported mean
absolute saturated fat intake in the Rotterdam study was 34.4 g/d.
In CHAP, median reported saturated fat intake was 18.5 g/d in the
middle quintile. In CAIDE, the range of reported saturated fat intake
in the second and third quartiles was from 4.2 to 15.8 g/d; given
that this was limited to fat from spreads, total saturated fat intake
would likely have been about twice this magnitude. The WHICAP
study did not report baseline saturated fat intake. As a percentage of
total energy intake, however, the mean level of saturated fat intake
in the Rotterdam Studymay not have been unusual (Engelhart et al.,
2002a).
The variability in saturated fat intake in the Rotterdam Study
appears to have been limited, judging by the similarity between the
lowest and highest tertiles (Table 1). These observations suggest
that the high and rather uniform saturated fat intake in the Rot-
terdam Study cohort would be likely to blunt any observable effect
of saturated fat intake.
Rotterdam participants also reportedly had an unusually high
vitamin E intake (13.9 mg/d, compared with 9.0 mg/d in CHAP)
(Engelhart et al., 2002a; Morris et al., 2003). High vitamin E intake
was associated with reduced Alzheimer’s risk in the Rotterdam
Study (Englehart et al., 2002b) and other prospective studies
(Devore et al., 2010; Morris et al., 2005).
Similar considerations may apply to studies of MCI. The one
study (CAIDE) that identiﬁed an association between saturated fat
intake and MCI risk assessed diet at a mean age of 50 years, with
an ensuing 21 years follow-up (Eskelinen et al., 2008). The PATH
Through Life Study observed individuals only until a mean age of
66.5 years, identifying only 10 MCI cases, <1% of participants in
this comparatively young cohort (Cherbuin and Anstey, 2012). On
the other hand, the Rochester Epidemiology Project began obser-
vation with individuals whose median age was 79.5 years, ending
observation 3.7 years later (Roberts et al., 2012). The more
advanced age of this cohort may account both for the higher case
ﬁnding and, if a degree of cognitive impairment eventually man-
ifests in many elderly people, the lack of apparent effect of satu-
rated fat intake. The remaining cohort study, ILSA, was muchsmaller and may have had little statistical power (Solfrizzi et al.,
2006a).
For studies of cognitive function, the 2 studies that identiﬁed
associations between saturated fat intake and cognitive decline
over time (Morris et al., 2004; Okereke et al., 2012) were much
larger than the 2 that did not ﬁnd associations. One of the negative
studies (Solfrizzi et al., 2006b) had the advantage of a long obser-
vation period (8.5 years), but had a high dropout rate, a hazard of
lengthy studies in elderly people.
4.1. Mechanisms
Several possible mechanisms link saturated or trans fat intake to
dementia risk. Both types of fat tend to elevate plasma total and
low-density lipoprotein cholesterol concentrations which, in turn,
may be associated with AD risk. In a study of 9844 Kaiser Perma-
nente patients, serum cholesterol levels drawn inmidlife (mean age
42 years) were associatedwith AD risk nearly 3 decades later (mean
age 69 years) (Solomon et al., 2009).
Cholesterol may play a key role in b-amyloid production and
deposition (Puglielli et al., 2001). Although it may be intracellular
cholesterol distribution, not circulating cholesterol concentrations,
that regulates b-amyloid generation, the boundaries between the
roles of cholesterol in the plasma and in the brain are not clear. In a
postmortem study of 64 individuals with AD, serum total and LDL
cholesterol concentrations were associated with the quantity of b-
amyloid N-42, but not with the less pathogenic b-amyloid N-40, in
the cerebral cortex. These associations were independent of APOE
genotype (Kuo et al., 1998).
Supporting the role of cholesterol in dementia risk is the fact
that cholesterol-lowering statin drugs have been associated with
reduced Alzheimer’s risk in some, although not all, studies. In the
Rotterdam study, after 9 years of follow-up, statin use was associ-
ated with a roughly 50% reduction in AD risk (Haag et al., 2009).
Similarly, in a study of 1789 Latinos living in the Sacramento area,
statin use was associated with a similar reduction of dementia or
cognitive impairment during a 5-year follow-up period, after
adjustment for education, smoking status, the presence of the
APOE ε4 allele, and history of diabetes or stroke (Cramer et al.,
2008). The Prospective Study of Pravastatin in the Elderly (PROS-
PER) (Shepherd et al., 2002) and the Medical Research Council/
British Heart Foundation Heart Prevention Study (Collins et al.,
2002) did not support a preventive effect of statin use on demen-
tia, perhaps because of design differences. In a recent meta-
analysis, statin users were at signiﬁcantly reduced risk of AD
(relative risk [RR], 0.70; 95% CI, 0.60e0.83) and of dementia overall
(RR, 0.82; 95% CI, 0.69e0.97) (Wong et al., 2013).
Although amodiﬁcation in cholesterol concentrations or activity
is an attractive explanation for the apparent protective effect of
statins and of low-saturated fat diets in relation to AD, the Rotter-
dam study presented a complication. In this cohort, a reduction in
AD risk was found for statin users but not for users of cholesterol-
lowering drugs of other classes (Haag et al., 2009), raising the
possibility that the reduction in AD risk observed with statin use
may occur by a mechanism other than their effect on cholesterol or
that passage into the central nervous system, which varies among
lipid-lowering medication classes, may be at issue.
Some studies have suggested that the effect of saturated fat
intake on Alzheimer’s risk may be most evident in (or even limited
to) carriers of the APOE ε4 allele. The ApoE protein produced by the
APOE gene is a major plasma apolipoprotein and the primary
cholesterol carrier in the brain (Puglielli et al., 2003). As a group,
APOE ε4 carriers have higher plasma total and LDL concentrations
compared with APOE ε3 homozygotes (Bennett et al., 2007).
Moreover, APOE status may inﬂuence the relationship between
N.D. Barnard et al. / Neurobiology of Aging 35 (2014) S65eS73S72dietary intake and plasma lipid concentrations; a greater effect of
dietary saturated fat on LDL cholesterol concentrations has been
observed among APOE ε4 carriers (Rubin and Berglund, 2002). In a
substudy of the European Prospective Investigation of Cancer and
Nutrition (EPIC), saturated fat intake correlated signiﬁcantly with
serum LDL cholesterol concentrations only in individuals carrying
the ε4 allele (Loktionov et al., 2000).
It should be noted that the current widespread use of statins
complicates efforts to isolate the effects of diet on cognitive func-
tion. If saturated or trans fats inﬂuence cognition because of their
effect on cholesterol metabolism, the use of cholesterol-lowering
drugs would be expected to mask that effect.
Apart from their effect on cholesterol concentrations, dietary
saturated fats also contribute to insulin resistance and diabetes, pre-
sumablyby theaccumulationof intracellularorcellmembrane lipid in
skeletal muscle, liver, and pancreatic tissues (Haag and Dippenaar,
2005; Samuel et al., 2010). Individuals with type 2 diabetes are at
greatly increased risk of developing AD (Ohara et al., 2011). Possible
mechanisms (which are not mutually exclusive) include diabetes’
contribution to cerebrovasculardisease, glucose toxicity in the formof
glycationof brainproteins ormicrovascular changes, a contribution of
hyperinsulinemia to vasculature damage, increased b-amyloid
secretion, or reduced b-amyloid elimination (Biessels, 2006). It may
be that cardiovascular risk factors, including hypercholesterolemia
and diabetes, increase the risk of cerebral white matter lesions,
resulting in mental decline (Breteler et al., 1994).4.2. Limitations
This review has important limitations. The limited number of
available observational studies and the absence of intervention trials
reﬂect the challenges of conducting such studies and suggest that
caution is needed in drawing conclusions. Attrition is a challenge in
studies of elderly people, and individuals with cognitive problems
may bemost likely to be lost to follow-up. The variation inmeans of
reporting dietary intake and its relationship to cognitive problems
presents a barrier to combining the results of studies. The limitations
of the included studies are carried forward in the meta-analysis.5. Conclusion
Several, although not all, prospective studies indicate relation-
ships between saturated and trans fat intake and risk of cognitive
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